Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study - Robert, C; Ribas, A; Schachter, J (Lancet Oncol, 2019)
et al.